Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 26, 2015 10:48 AM ET


Company Overview of SteadyMed Therapeutics, Inc.

Company Overview

SteadyMed Therapeutics, Inc. engages in the development and commercialization of prefilled, size efficient, disposable, subcutaneous liquid drug delivery systems. Its PatchPumps technology is customized to deliver liquid drugs, including biologics with a range of volumes and viscosities. The company was founded in 2005 and is based in San Ramon, California.

2410 Camino Ramon

Suite 285

San Ramon, CA 94583

United States

Founded in 2005



Key Executives for SteadyMed Therapeutics, Inc.

Chief Executive Officer and Director
Age: 46
Co-Founder and Vice President of Business Development
Co-Founder and Director
Vice President of Operations
Chief Technical Officer and Executive Vice President of R&D
Age: 47
Compensation as of Fiscal Year 2014.

SteadyMed Therapeutics, Inc. Key Developments

SteadyMed Therapeutics, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015

SteadyMed Therapeutics, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

SteadyMed Therapeutics, Inc. Announces Management Appointments

SteadyMed Therapeutics, Inc. announced that Peter Noymer has joined the company as EVP of R&D and CTO, and Rick White has joined as VP BD and Commercial Operations. Peter is responsible for completing the development of the company's PatchPump(R) parenteral drug delivery technology as well as clinical and regulatory affairs for SteadyMed's PatchPump drug product to treat Pulmonary Arterial Hypertension (PAH). Previously, he was VP of Product R&D at Alexza Pharmaceuticals, where he worked on several development programs on combination products for novel therapies, including Adasuve(R), the first inhalable treatment for acute agitation. Prior to that, he held senior management positions at Aradigm Corporation and was a Visiting Assistant Professor at Carnegie Mellon University. Rick is responsible for both Business Development activities related to the licensing of PatchPump technology to BioPham companies, for delivery of high volume biologic products, as well as the initiation of pre-commercial activities relating to PatchPump drug product to treat PAH. Most recently Rick was VP of BD & Marketing at Ligand Pharmaceuticals where he was successful in executing drug delivery technology licenses with both large and small Pharma companies, as well as multiple product licensing initiatives.

Similar Private Companies By Industry

Company Name Region
Grand River Technologies, Inc. United States
Genetic Identification Services, Inc. United States
LifeSensors, Inc. United States
Adventus Americas, Inc. United States
NX Development Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SteadyMed Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at